OutSee Completes Seed Funding Round and Establishes Partnership With o2h Discovery for Lead Drug Target Candidate
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5M seed funding round. The Company also announced the signing of a strategic agreement with o2h discovery, a preclinical Contract Research Organisation with an integrated drug discovery platform. The partnership aims to launch a collaborative drug discovery programme for OutSee’s lead target candidate, identified through the Company’s state-of-the-art genomic target discovery and precision medicine platform, Nomaly.
OutSee Raises £1.8M Seed Funding to Expand Therapeutic Pipeline Using Predictive Genomics
OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced it has secured £1.8M in seed funding, led by Ahren Innovation Capital and with additional investment from Kadmos Capital, Empirical Ventures and Panacea Ventures. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the Company’s in-house target discovery program and establishing new strategic partnerships with leading pharma and biotech companies.
